Suppr超能文献

抗精神病药物与精神分裂症患者的睡眠问题。

Antipsychotic medications and sleep problems in patients with schizophrenia.

机构信息

Finnish Institute for Health and Welfare, Finland; Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Finland; SleepWell Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Finland.

Finnish Institute for Health and Welfare, Finland.

出版信息

Schizophr Res. 2024 May;267:230-238. doi: 10.1016/j.schres.2024.03.015. Epub 2024 Apr 4.

Abstract

BACKGROUND

Sleep problems are common and related to a worse quality of life in patients with schizophrenia. Almost all patients with schizophrenia use antipsychotic medications, which usually increase sleep. Still, the differences in subjective sleep outcomes between different antipsychotic medications are not entirely clear.

METHODS

This study assessed 5466 patients with schizophrenia and is part of the nationwide Finnish SUPER study. We examined how the five most common antipsychotic medications (clozapine, olanzapine, quetiapine, aripiprazole, and risperidone) associate with questionnaire-based sleep problems in logistic regression analyses, including head-to-head analyses between different antipsychotic medications. The sleep problems were difficulties initiating sleep, early morning awakenings, fatigue, poor sleep quality, short (≤6 h) and long sleep duration (≥10 h).

RESULTS

The average number of antipsychotic medications was 1.59 per patient. Clozapine was associated with long sleep duration (49.0 % of clozapine users vs 30.2 % of other patients, OR = 2.05, 95 % CI 1.83-2.30, p < .001). Olanzapine and risperidone were in head-to-head analyses associated with less sleep problems than patients using aripiprazole, quetiapine, or no antipsychotic medication. Aripiprazole and quetiapine were associated with more insomnia symptoms and poorer sleep quality. Patients without antipsychotic medications (N = 159) had poorer sleep quality than patients with antipsychotic use, and short sleep duration was common (21.5 % of patients not using antipsychotics vs 7.8 % of patients using antipsychotics, OR = 2.97, 95 % CI 1.98-4.44, p < .001).

CONCLUSIONS

Prevalence of sleep problems is markedly related to the antipsychotic medication the patient uses. These findings underline the importance of considering and assessing sleep problems when treating schizophrenia patients with antipsychotics.

摘要

背景

睡眠问题在精神分裂症患者中很常见,且与生活质量较差有关。几乎所有精神分裂症患者都使用抗精神病药物,这些药物通常会增加睡眠。然而,不同抗精神病药物的主观睡眠结果差异并不完全清楚。

方法

本研究评估了 5466 名精神分裂症患者,是全国性芬兰 SUPER 研究的一部分。我们在逻辑回归分析中检查了五种最常见的抗精神病药物(氯氮平、奥氮平、喹硫平、阿立哌唑和利培酮)与基于问卷的睡眠问题之间的关系,包括不同抗精神病药物之间的头对头分析。睡眠问题包括入睡困难、早醒、疲劳、睡眠质量差、睡眠时间短(≤6 小时)和长(≥10 小时)。

结果

每位患者平均使用 1.59 种抗精神病药物。氯氮平与长睡眠时间有关(使用氯氮平的患者中有 49.0%,而其他患者为 30.2%,OR=2.05,95%CI 1.83-2.30,p<.001)。奥氮平和利培酮与较少的睡眠问题相关,而与使用阿立哌唑、喹硫平或未使用抗精神病药物的患者相比。阿立哌唑和喹硫平与更多的失眠症状和更差的睡眠质量有关。未使用抗精神病药物的患者(N=159)睡眠质量比使用抗精神病药物的患者差,且短睡眠时间很常见(未使用抗精神病药物的患者中有 21.5%,而使用抗精神病药物的患者中有 7.8%,OR=2.97,95%CI 1.98-4.44,p<.001)。

结论

睡眠问题的患病率与患者使用的抗精神病药物明显相关。这些发现强调了在使用抗精神病药物治疗精神分裂症患者时,考虑和评估睡眠问题的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验